Such a move will be positive for Indian drugmakers such as Biocon, Dr. Reddy’s Laboratories, Lupin and Sun Pharma, who have exposure to the biosimilars market in the US.
Such a move will be positive for Indian drugmakers such as Biocon, Dr. Reddy’s Laboratories, Lupin and Sun Pharma, who have exposure to the biosimilars market in the US.